logo
ResearchBunny Logo
S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression

Medicine and Health

S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression

X. Wang, Z. Qiu, et al.

Explore the groundbreaking findings of Xuehong Wang and colleagues as they unveil the pivotal role of S1PR1 in angiogenesis and the progression of hepatocellular carcinoma (HCC). This research reveals how S1PR1's regulation can be a key therapeutic target, offering hope in the fight against HCC. Discover the exciting mechanisms that put S1PR1 at the forefront of new cancer therapies.

00:00
00:00
~3 min • Beginner • English
Abstract
Angiogenesis is a fundamental process underlying the occurrence, growth and metastasis of hepatocellular carcinoma (HCC), a prevalent tumour type with an extremely poor prognosis due to abundant vasculature. However, the underlying mechanism of angiogenesis in HCC remains largely unknown. Herein, we found that sphingosine-1-phosphate receptor 1 (S1PR1) plays an important role in HCC angiogenesis. S1PR1 was found to be selectively and highly expressed in the blood vessels of HCC tissues compared with those of paratumour tissues. Functionally, high expression of S1PR1 in endothelial cells (ECs) promoted angiogenesis and progression of HCC in vitro and in vivo. Mechanistically, proangiogenic factors (S1P, IL-6, VEGFA) in conditioned medium from HCC cells induced the upregulation of S1PR1 in ECs via the phosphorylation of STAT3 at Y705. Further study also revealed that S1PR1 promotes angiogenesis by decreasing ceramide levels via CerS3 downregulation. Interestingly, we demonstrated that S1PR1 downregulates CerS3 by inducing CerS6 translocation into the nucleus to inhibit CerS3 at the transcriptional level in ECs. In addition, we found that a high concentration of Lenvatinib significantly downregulated the expression of S1PR1 and obviously enhanced S1PR1 knockdown-mediated angiogenesis inhibition, indicating that S1PR1 may be a target by which Lenvatinib combats angiogenesis in HCC. Thus, S1PR1 may be an important target for suppressing angiogenesis in HCC, and inhibiting S1PR1 is a promising approach to antitumor therapy in HCC.
Publisher
Cell Death and Disease
Published On
Sep 06, 2022
Authors
Xuehong Wang, Zhidong Qiu, Wei Dong, Zebin Yang, Junnan Wang, Hailiang Xu, Tian Sun, Zhaoquan Huang, Junfei Jin
Tags
angiogenesis
hepatocellular carcinoma
S1PR1
vascular development
therapeutic target
STAT3
lenvatinib
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny